The US FDA approved the first generic version of GlaxoSmithKline PLC's blockbuster asthma drug Advair Diskus (fluticasone propionate/salmeterol) Jan. 30 in a big win for Mylan NV. The approval underscores the R&D investment the company has put behind developing complex generics and biosimilars.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?